Celcuity Inc.
$88.95
+3.8%Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -23.5).
Valuation inputs: P/E -23.5, earnings yield N/A, momentum +3.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.8%, ROIC -40.8%).
Profitability stack: net margin 0.0%, ROE -1.8%, ROIC -40.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +78.4%, momentum +3.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Celcuity Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Celcuity Inc. Fair Value Envelope
No Revenue Data
CELC has not reported any revenue values in the available annual periods.
Celcuity Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CELC has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CELC has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CELC has not reported any net profit margin values in the available annual periods.
Celcuity Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Celcuity Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Celcuity Inc. Street Expectations Map
Wall Street analysts project that CELC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 153.22, with estimates ranging from a low of 110.00 to a high of 171.00.
The consensus 1-year price target stands at 153.22, with estimates ranging from a low of 110.00 to a high of 171.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Celcuity Inc. Insider Positioning
During the last 12 months, insiders have purchased $786K and sold $8.59M worth of CELC shares, resulting in $7.80M of net selling activity.
3 Months
0
0.00
28.6K
3.95M
-3.9M
-$3.95M
3-6 Months
0
0.00
20.0K
2.40M
-2.4M
-$2.40M
6-9 Months
14.0K
785.73K
21.5K
2.14M
-1.4M
-$1.36M
9-12 Months
0
0.00
2.0K
93.25K
-93K
-$93K
Top Buyers
Baker Bros. Advisors Lp
10 Percent Owner
$786K
Top Sellers
Dalvey David
Director
$7.51M
Buller Richard E
Director
$1.07M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.80M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
No Dividend Yield Data
CELC has not reported any dividend yield values in the available annual periods.
celc Dividend History
Learning Layer
Related Guides
Build conviction on CELC by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.